SCHEMBL499064

SCHEMBL499064

CCC(C)(C)C(=O)C(=O)N1CCCC[C@H]1C(=O)O

nearest known ligand 0.72

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
FKBP1A P62942 14/20 0.72

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5966171 1.00 FKBP1A (0.72) FKBP1A
SCHEMBL4675555 1.00 FKBP1A (0.72) FKBP1A
Gpi-1485 SCHEMBL3568704 0.95 FKBP1A (0.66) FKBP1A
Gpi-1485 SCHEMBL2006950 0.95 FKBP1A (0.66) FKBP1A
Trifluoroacetic Acid SCHEMBL499188 0.93 FKBP1A (0.64) FKBP1A
SCHEMBL6317432 0.89 FKBP1A (0.57) FKBP1A
SCHEMBL7755136 0.88 FKBP1A (0.58) FKBP1A
SCHEMBL4684233 0.88 FKBP1A (0.69) FKBP1A
SCHEMBL4679982 0.88 FKBP1A (0.69) FKBP1A
SCHEMBL5700567 0.88 FKBP1A (0.69) FKBP1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080085238-A1 Small Molecules for Imaging Protein-Protein Interactions The Government of the United States of America as represented (US) 2008-04-10 US claimed
EP-1227859-B1 NEUROPHILIN LIGANDS FOR TREATING OCULAR CONDITIONS ALCON INC (CH) 2006-08-09 EP claimed
JP-2002522485-A 2002-07-23 JP claimed
US-6376517-B1 FOR TREATING VISION LOSS, PREVENTING VISION DEGENERATION, AND PROMOTING VISION REGENERATION (?NEOPSIS?) GPI NIL HOLDINGS, INC. 2002-04-23 US claimed
EP-0777478-B1 INHIBITORS OF ROTAMASE ENZYME ACTIVITY GUILFORD PHARM INC (US) 2001-11-07 EP claimed
US-20010036947-A1 Pipecolic acid derivative hair growth compositions and uses GPI NIL HOLDINGS, INC. (US) 2001-11-01 US claimed
EP-1109554-A2 PIPECOLIC ACID DERIVATIVES FOR VISION AND MEMORY DISORDERS GPI NIL Holdings, Inc. (US) 2001-06-27 EP claimed
WO-2000009109-A2 PIPECOLIC ACID DERIVATIVES FOR VISION AND MEMORY DISORDERS GPI NIL HOLDINGS, INC. (US) 2000-02-24 WO claimed
US-5843960-A Inhibitors of rotamase enzyme activity GPI NIL HOLDINGS, INC. (US) 1998-12-01 US claimed
US-12594275-B2 Immunophilin binding agents and uses thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2026-04-07 US disclosed
US-12558356-B2 Immunophilin binding agents and uses thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2026-02-24 US disclosed
US-20250108052-A1 IMMUNOPHILIN BINDING AGENTS AND USES THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2025-04-03 US disclosed
EP-4242304-A2 METHODS AND REAGENTS FOR ANALYZING PROTEIN-PROTEIN INTERFACES Warp Drive Bio, Inc. (US) 2023-09-13 EP disclosed
EP-4242304-A2 METHODS AND REAGENTS FOR ANALYZING PROTEIN-PROTEIN INTERFACES Warp Drive Bio, Inc. (US) 2023-09-13 EP disclosed
US-6133456-A DIMERS OF THE MACROCYCLIC NATURAL PRODUCT, FK506, COVALENTLY ATTACHED TO EACH OTHER VIA A SYNTHETIC LINKER MOIETY ARIAD GENE THERAPEUTICS, INC. (US) 2000-10-17 US disclosed
EP-1011650-A1 METHOD FOR PREVENTING AND TREATING HEARING LOSS USING SENSORINEUROTROPHIC COMPOUNDS Amgen Inc., (US) 2000-06-28 EP disclosed
WO-2000016603-A2 BRIDGED HETEROCYCLIC DERIVATIVES GPI NIL HOLDINGS, INC. (US) 2000-03-30 WO disclosed
WO-2000009109-A2 PIPECOLIC ACID DERIVATIVES FOR VISION AND MEMORY DISORDERS GPI NIL HOLDINGS, INC. (US) 2000-02-24 WO disclosed
WO-1999014998-A2 METHOD FOR PREVENTING AND TREATING HEARING LOSS USING SENSORINEUROTROPHIC COMPOUNDS AMGEN INC. (US) 1999-04-01 WO disclosed
US-5786378-A FKBP TYPE IMMUNOPHILLINS FOR NERVOUS SYSTEM DISORDERS GPI NIL HOLDINGS, INC. (US) 1998-07-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080085238-A1 Small Molecules for Imaging Protein-Protein Interactions HSPBP1, HSPA2, HSPA8 FKBP1A 1547/4885
US-20010036947-A1 Pipecolic acid derivative hair growth compositions and uses PIP5K1C, PIP4K2C, PIP5K1A FKBP1A 510/4885
US-12594275-B2 Immunophilin binding agents and uses thereof CCR1, CCRL2, CCR3 FKBP1A 1251/4885
US-20250108052-A1 IMMUNOPHILIN BINDING AGENTS AND USES THEREOF SERPINA6, SELPLG, FABP7 FKBP1A 376/4885
US-12558356-B2 Immunophilin binding agents and uses thereof CCRL2, CFB, CCR3 FKBP1A 2027/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.